NanoViricides (NYSE:NNVC) Downgraded to Sell Rating by StockNews.com

StockNews.com cut shares of NanoViricides (NYSE:NNVC) from a hold rating to a sell rating in a research report released on Friday.

NanoViricides Stock Performance

NNVC stock traded down $0.05 during mid-day trading on Friday, hitting $1.44. 114,103 shares of the company were exchanged, compared to its average volume of 143,195. NanoViricides has a 1-year low of $1.00 and a 1-year high of $3.59. The firm’s 50 day simple moving average is $1.52 and its 200 day simple moving average is $1.81. The firm has a market cap of $20.09 million, a P/E ratio of -2.06 and a beta of 0.96.

NanoViricides (NYSE:NNVC) last issued its quarterly earnings data on Friday, September 27th. The company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NanoViricides stock. Renaissance Technologies LLC grew its position in shares of NanoViricides, Inc. (NYSE:NNVC) by 20.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 102,100 shares of the company’s stock after acquiring an additional 17,600 shares during the quarter. Renaissance Technologies LLC owned 0.86% of NanoViricides worth $176,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.30% of the company’s stock.

NanoViricides Company Profile

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.